Provided by Tiger Fintech (Singapore) Pte. Ltd.

Incyte

60.58
+0.24000.40%
Post-market: 60.580.00000.00%16:10 EDT
Volume:2.28M
Turnover:138.58M
Market Cap:11.72B
PE:403.87
High:61.75
Open:60.26
Low:60.21
Close:60.34
Loading ...

Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa

THOMSON REUTERS
·
17 Mar

Incyte Corp - Statistically Significant Results in Both Stop-Hs1 and Stop-Hs2 Studies

THOMSON REUTERS
·
17 Mar

Incyte Corp. Stock Underperforms Tuesday When Compared To Competitors

Dow Jones
·
12 Mar

Eli Lilly-Incyte Partnered FDA-Approved Drug Shows Encouraging Efficacy In Adolescent Patients With Patchy Hair Loss

Benzinga
·
11 Mar

Incyte’s Mixed Trial Results and Strong Financial Position Lead to Hold Rating

TIPRANKS
·
11 Mar

Incyte Releases Mixed Data From Late-Stage Opzelura Studies In Skin Disease Characterized By Itchy Firm Lumps

Benzinga
·
11 Mar

INCY Opzelura Shows Superior Efficacy in 2 Prurigo Nodularis Studies

Zacks
·
10 Mar

LLY/INCY Olumiant Shows Superior Efficacy in Pediatric Alopecia Study

Zacks
·
10 Mar

Positive Outlook for Incyte Amid Mixed TRuE-PN Results and Anticipated Phase III Catalyst

TIPRANKS
·
10 Mar

Incyte (INCY) Receives a Hold from Stifel Nicolaus

TIPRANKS
·
10 Mar

Eli Lilly, Incyte Report Significant Hair Regrowth in Adolescents Treated With Baricitinib

MT Newswires Live
·
10 Mar

Incyte’s Promising Clinical Trials and Strategic Growth Potential Support Buy Rating

TIPRANKS
·
10 Mar

TD Cowen Reaffirms Their Buy Rating on Incyte (INCY)

TIPRANKS
·
10 Mar

Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study

PR Newswire
·
09 Mar

BRIEF-Incyte Corp Says Phase 3 True-Pn1 Study Meets All Primary And Key Secondary Endpoints

Reuters
·
08 Mar

Incyte - Topline Data From Separate Phase 3 Study, True-Pn2, Showed That Primary Endpoint Did Not Reach Statistical Significance

THOMSON REUTERS
·
08 Mar